Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q2 2025 · 10-Q
Revenue$10.00M$10.00M−50.2% vs Q2 2024 Net Income-$13.55M-$13.55MN/M vs Q2 2024 EPS Diluted-$0.14-$0.14N/M vs Q2 2024 Operating Income-$11,368,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,021,000N/M Margins · derivedOperating margin-113.6%−113.9 pt vs Q2 2024
Net margin-135.4%−121.8 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 11, 2025 · 42 d after period end